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Although the era of gene therapy for human disease is relatively recent and brief to date, a succession of distinct phases can be recognized already by the rapidly expanding clinical horizons for correcting disease through the introduction of new genes.1,2 An initial period was focused on the strategy and expectation that hereditary disorders caused by the lack of a needed protein would be prevented by inserting normal copies of the gene into the germ line of affected patients or even unaffected heterozygotes who carried the mutation. In retrospect, although this assumption appeared logical enough at the time, daunting technical and ethical concerns soon were appreciated, such as the risks of inadvertent mutations caused by manipulation of germ line DNA, incomplete knowledge of the genetic sequences necessary to ensure accurate spatial and temporal expression of the curative gene, and inherent irreversibility of the approach. These limitations were compounded by the philosophical or social controversy concerning therapy directed at the germ line, which remains unresolved. Technical obstacles have also frustrated therapy directed at hematopoietic stem cells, the multipotential precursors of several lineages. Consequently, the field now is dominated by the contrasting paradigm of somatic cell gene therapy, the goal of modifying differentiated somatic cells with a therapeutic gene, not only for the single-gene disorders originally envisioned as the realm of this research but also for the acquired diseases encountered more commonly in clinical practice. Thus, gene therapy now must be envisioned as one potential way to deliver therapeutic proteins (or alter the expression of a patient's own proteins) for, inherently, any disease.
Given this goal of introducing foreign DNA to an appropriate organ in vivo, a number of generic methods exist, involving gene delivery by DNA deficiency as a priority for gene therapy research include extraordinarily efficient uptake of adenovirus by liver even with systemic injection,9.10 the opportunity for portal vein injection of virus"' or engineered cells, the likelihood that relatively broad ranges of gene expression will be tolerated, the early lethality of LDL receptor mutations, and the potential implications for augmenting LDL receptor abundance in more common forms of hyperlipidemia.
To test whether adenovirus-mediated delivery might be effective for modifying cholesterol levels in vivo, mice were inoculated intravenously with recombinant adenovirus encoding the human LDL receptor driven by the cytomegalovirus promoter or the enzyme firefly luciferase as a convenient reporter protein.'0 Under these conditions, more than 99% of virus-dependent luciferase expression was detected in the liver, the predominant site for cholesterol catabolism. Levels of LDL receptor in liver were increased 10-fold 4 days after injection, and the human receptor was detected in roughly 90% of liver cells. "'I-LDL clearance was increased as much as 10-fold, and steady-state cholesterol levels declined.10 Mutant mice lacking LDL receptor were generated by the technique of homologous recombination in embryonic stem cells'2: injection with the virus encoding LDL receptor restored expression of receptor to the liver, accelerated the clearance of verylow-density lipoprotein (VLDL) (which was impaired by the mutation 30-fold, even more dramatically than LDL), and corrected the lipoprotein profile of the hypercholesterolemic, receptor-deficient mice.12
A reciprocal strategy to protect against or reverse atherosclerosis is based on augmentation of circulating high-density lipoprotein (HDL) cholesterol: In mice, intravenous injection of recombinant adenovirus encoding human apolipoprotein (apo) A1 results in overexpression of apo A1 and, consequently, increasing HDL cholesterol to levels that are known to be protective in humans.'3 Apo Al, like other secreted, circulating proteins, is particularly amenable to a gene transfer strategy, since virtually any somatic cell could be targeted to serve as a source of the gene product.
Adenoviral Gene Therapy for Hereditary Myopathies By contrast, gene delivery to muscle itself will be required for Duchenne (DMD) and Becker muscular dystrophies X-linked disorders caused by absence or abnormalities, respectively, of the sarcolemmal protein, dystrophin. Myoblast transfer'4 and direct injection of plasmids encoding dystrophin'S have been used in efforts to restore dystrophin expression in DMD patients or dystrophin-deficient mdx mice, yet daunting limitations are inherent to both techniques that rely on local injection -the total mass of skeletal muscle needing correction, the distribution and inaccessibility of respiratory muscles on which the clinical outcome largely depends, the concurrent need to restore dystrophin expression in myocardium, and the meager efficiency for dystrophin-positive muscle fibers. Much as injecting mouse skeletal muscle with adenovirus encoding the marker gene Escherichia coli 3-galactosidase (lacZ) '6 labeled more extensive muscle segments than did plasmid injection,'7 adenovirus was at least 10- lymphocytes,42 or myoblasts4344 that have been engineered in culture to harbor and express foreign genes. However, despite the emerging importance of direct injection as a means to understand cardiac gene regulation in vivo, its ultimate merit for therapeutic purposes may be diminished both by intrinsic invasiveness and by the potential need to modify ventricular muscle with much greater uniformity than has been achieved to date; secreted proteins, including angiogenic factors, may be plausible counterexamples to this last concern.45 In the case of ex vivo therapy, cells appropriate for implantation in the heart, capable of electrical and mechanical integration, have not yet been identified.
Consequently, the fact that adenoviruses infect nonreplicating cells, together with evidence discussed previously for more extensive gene delivery in skeletal muscle by adenovirus than by plasmid DNA, has heightened interest in this class of virus for gene transfer to myocardium itself. Encouraging this prospect, recombinant adenovirus mediates remarkably uniform gene transfer to adult cardiac cells in culture.46 Preliminary studies report initial success for adenovirus-mediated gene transfer to the adult ventricular myocardium in vivo, by local injection47 or coronary artery infusion. 48 Apart from the direct clinical implications of this research, adenovirus-mediated gene delivery provides a system for investigating the DNA elements and regulatory circuits that control growth and gene expression in the heart.
Challenges and Priorities
Alternatives to adenovirus for cardiovascular gene therapy include not only retrovirus, naked DNA, and cellmediated gene transfer-whose strengths and limitations have been acknowledged-but also synthetic delivery systems for receptor-mediated DNA uptake, which has been achieved in vivo using a liver-specific ligand, asialoglycoprotein. 49 Technical concerns, of which potential users should be made aware, include possible contamination of replication-defective recombinants with virus competent for replication, inadvertent deletion or mutation of the eukaryotic expression cassette in the course of recombination, and, perhaps most important, the complexity of this system by comparison with conventional plasmids or retroviruses, which are easier to engineer. Thus, the utility of adenovirus is most compelling in experimental or clinical settings where simpler procedures are ineffective or inefficient. The theoretical risk for complementation of replication-defective viruses by wild-type adenovirus is expected to be minute in cardiac and vascular muscle but deserves examination in the respiratory tract, given the imminence of clinical trials evaluating adenovirus-mediated delivery of the gene for the cystic fibrosis transmembrane conductance regulator. 56 In summary, recombinant adenovirus is one of several vehicles for gene delivery, which might hold the greatest promise for cells of the cardiovascular system. Although gene therapy for monogenic disorders such as LDL receptor deficiency and Duchenne's muscular dystrophy has received the fullest scrutiny thus far, the same approach, to re-engineer cell growth or function, is in theory well suited to the most prevalent forms of acquired heart disease.
